Skip to Content


Madison Alder, quoting Rachel Sachs (Academic Fellow Alumna)
Bloomberg Law
March 4, 2019

Read the Full Article

From the article:

"Eliminating certain drug rebates in federal health insurance programs is the one tool the Trump administration has to produce the biggest impact on pricing without the help of Congress, though even it isn’t sure how much this will help.

The proposed rule, released Feb. 1, would effectively get rid of incentives that drug manufacturers pay middlemen, called pharmacy benefit managers, during price negotiations for plans under Medicaid and the drug portion of Medicare."

Read more here!

Read the Full Article

Tags

pharmaceuticals   rachel sachs   regulation